| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -169,166 | -118,556 |
| Equity-based compensation expense | 28,728 | 19,261 |
| Accretion on marketable securities | -5,375 | -4,017 |
| Depreciation and amortization | 232 | 153 |
| Prepaid expenses and other assets | -6,057 | -5,259 |
| Accounts payable | 40 | 779 |
| Accrued expenses and other liabilities | 1,843 | -3,643 |
| Net cash used in operating activities | -137,641 | -100,764 |
| Maturities of marketable securities | 374,572 | 294,572 |
| Purchase of marketable securities | 216,936 | 204,366 |
| Purchases of property and equipment | 38 | - |
| Net cash provided by (used in) investing activities | 157,598 | 90,206 |
| Issuance of common stock under equity-based compensation plans | 373 | 373 |
| Issuance of common stock and pre-funded warrants, net of issuance costs | 0 | 0 |
| Acquisition of noncontrolling interests | 0 | 0 |
| Net cash provided by financing activities | 373 | 373 |
| Net increase in cash and cash equivalents | 20,330 | -10,185 |
| Cash and cash equivalents at beginning of period | 83,005 | - |
| Cash and cash equivalents at end of period | 103,335 | - |
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)